Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart clot showdown: new blood thinner vs. old standard in major trial

NCT ID NCT05825573

Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a newer type of blood thinner (DOA) works better than the standard one (VKA) for dissolving dangerous blood clots inside the heart. About 340 adults with such clots will be randomly assigned to one of the two treatments. The goal is to see which drug reduces the risk of death, stroke, or other serious events while causing fewer bleeding problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 340 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with a non-device related intra-cardiac thrombus (all localizations in the four cavities) diagnosed by echocardiography, cardiac CT-scanner or cardiac magnetic resonance imaging independently of underlying heart disease. * Anticoagulant naïve patient for at least 3 months * Patient affiliated to a health insurance program * Patient that accepted not to participate in other studies involving a study medication until the one-year follow-up visit. Registries and studies not involving a study drug are allowed. * Patient that signed the consent form Exclusion Criteria: * Active internal bleeding or recent (\< 6 months) major bleeding event requiring surgical procedure or transfusion * History of intracranial, intraocular, spinal bleeding or known intracranial neoplasm, arteriovenous malformation, or aneurysm * Severe, disabling stroke (modified Rankin score of 4 to 5, inclusive) within 3 months * Planned invasive procedure with potential for uncontrolled bleeding * Impaired hemostasis such as known International Normalized Ratio (INR) \>1.5; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/μL) * Severe chronic renal failure (creat. clearance\<30ml/min) * Known significant liver disease * Device related thrombus (mechanical valve prosthesis, left atrial appendage or septal closure devices, pacemaker leads) * Patients with mechanical valve prosthesis * Cardiogenic shock * Pregnancy or breast-feeding patient * Known allergy or hypersensitivity to VKA or DOA drugs * Inability or unwillingness to comply with study-related procedures * Participation in another clinical research protocol with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrolment in this trial (participation in a trial of routine care is authorized at the same time) * Patient under tutorship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Embolism heart failure ST-elevation myocardial infarction stroke disorder thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Intracardiac thrombus STEMI

Contacts and locations

Locations

  • AP-HM CHU La Timone

    Marseille, France

  • AP-HP CHU Bichat

    Paris, France

  • AP-HP CHU Lariboisière

    Paris, France

  • AP-HP Hopital Ambroise Paré

    Paris, France

  • Ap-Hp Hegp

    Paris, France

  • CH Bastia

    Bastia, France

  • CH Chartres

    Chartres, France

  • CH Compiègne Noyon

    Compiègne, France

  • CH Francois Mitterand

    Pau, France

  • CHR Metz-Thionville

    Metz, France

  • CHU Angers

    Angers, France

  • CHU Arnaud de Villeneuve

    Montpellier, France

  • CHU Brest

    Brest, France

  • CHU Gabriel Montpied

    Clermont-Ferrand, France

  • CHU La réunion NORD

    Saint-Denis, Reunion

  • CHU Lille

    Lille, France

  • CHU Limoges

    Limoges, France

  • CHU Nantes

    Nantes, France

  • CHU Nice

    Nice, France

  • CHU Pitié-Salpêtrière

    Paris, France

  • CHU Poitiers

    Potiers, France

  • CHU Rennes

    Rennes, France

  • CHU Strasbourg

    Strasbourg, France

  • CHU Toulouse

    Toulouse, France

  • CHU de Nimes

    Nîmes, France

  • Centre Cardiologique du Nord

    Saint-Denis, France

  • Centre Hopistalier de Valence

    Valence, 26000, France

  • Ch Auxerre

    Auxerre, 89000, France

  • Ch Avignon

    Avignon, France

  • Ch Bretagne Atlantique

    Vannes, 56000, France

  • Clinique du Millenaire

    Montpellier, France

  • Groupe Hospitalier Mutualiste

    Grenoble, France

  • Hôpital Cardiologique du Haut Lévêque

    Bordeaux, France

  • Hôpital Cardiovasculaire Louis Pradel

    Lyon, France

  • Hôpital Privé Dijon Bourgogne

    Dijon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.